Company / Revenue
Protalix BioTherapeutics, Inc. Revenue History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$65.5M
FY2025
5-year range
$38.4M / $65.5M
FY2021-FY2025
Trend
+37.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $38M to $65M over the past 2 years.
Based on SEC 10-K filings.
$65M in FY2025 with a 5-year CAGR of +13.9%.
Improved from $38M to $65M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +1.4%
- 5-Year CAGR
- +13.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +13.9%, indicating consistent growth.
- In FY2025, revenue increased 37.5% year-over-year.
- Lowest revenue in the period was in FY2015.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $65.5M | +37.5% |
| FY2024 | $47.6M | +24.2% |
| FY2023 | $38.4M | -39.0% |
| FY2022 | $62.9M | +15.0% |
| FY2021 | $54.7M | +59.7% |
| FY2020 | $34.2M | +62.4% |
| FY2019 | $21.1M | +383.0% |
| FY2017 | $4.4M | +23.9% |
| FY2016 | $3.5M | - |
| FY2015 | $0 | -100.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026